TNF-alpha inhibitors continue to be the preferred choice to treat psoriatic arthritis (PsA) following failure on conventional DMARDs. However, other biologics such as IL-17 inhibitors (e.g., Cosentyx, Taltz), the IL-12/23 inhibitor Stelara, IL-23 inhibitors (e.g., Tremfya), and targeted oral therapies (e.g., Xeljanz, Rinvoq) have begun to chip away at the TNF-alpha inhibitors’ patient share. Understanding the underlying unmet need in the treatment of PsA, as well as the factors that can differentiate products from one another, can determine an agent’s success in this competitive space. This report presents the key unmet needs in the treatment of PsA and provides the tools to make strategic decisions and assessments pertaining to this therapy market.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 34 European rheumatologists and dermatologists fielded in February 2023
Key companies: AbbVie, Amgen, Pfizer, Janssen, Novartis, Eli Lilly
Key drugs: Humira, Cosentyx, Taltz, Stelara, Tremfya, Xeljanz, Rinvoq